Immunosuppressive therapies increase the susceptibility of patients to infections. The current pandemic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) compels clinicians to develop recommendations for successful clinical management and surveillance of immunocompromised patients at high risk for severe disease progression. With only few case studies published on SARS-CoV-2 infection in patients with rheumatic diseases, we report a 25-year-old male who developed moderate coronavirus disease 2019 (COVID-19) with fever, mild dyspnea, and no major complications despite having received high-dose prednisolone, cyclophosphamide, and rituximab for the treatment of highly active, life-threatening eosinophilic granulomatosis with polyangiitis (EGPA).
【저자키워드】 COVID-19, SARS-CoV-2, Immunosuppression, rituximab, Vasculitis, Cyclophosphamide, EGPA, eosinophilic granulomatosis with polyangiitis, 【초록키워드】 Treatment, coronavirus disease, Rheumatic diseases, coronavirus, pandemic, SARS-COV-2 infection, susceptibility, Immunocompromised patient, infections, Surveillance, Fever, Dyspnea, male, Patient, Complication, Clinical management, Mild, moderate, immunosuppressive therapy, high risk, Prednisolone, High-dose, acute respiratory syndrome, clinician, life-threatening, severe disease progression, recommendation, develop, highly active, 【제목키워드】 granulomatosis, polyangiitis, Eosinophilic,